Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Company Overview - Entrada Therapeutics is a clinical-stage biopharmaceutical company focused on developing a new class of medicines that target intracellular mechanisms previously deemed inaccessible [2] - The company utilizes its proprietary Endosomal Escape Vehicle (EEV™) technology to enhance the intracellular delivery of therapeutics across various organs and tissues, aiming to improve therapeutic efficacy [2] - Entrada is advancing a diverse portfolio of RNA- and protein-based programs, particularly targeting neuromuscular and ocular diseases [2] Product Development - The lead oligonucleotide programs are aimed at treating patients with Duchenne muscular dystrophy who are amenable to exon 44, 45, 50, and 51 skipping [2] - Entrada has partnered to develop VX-670, a clinical-stage program for myotonic dystrophy type 1 [2] Upcoming Events - Dipal Doshi, the CEO of Entrada Therapeutics, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 3:45 PM PT [1] - A live webcast of the presentation will be available on Entrada's Investor Relations website and will be archived for 30 days post-event [1]